Duration of Anticoagulation Treatment for Thrombosis in APS: Is It Ever Safe to Stop?
- 832 Downloads
Antiphospholipid syndrome (APS) is an auto-immune thrombophilia for which anti-thrombotic medication is necessary for long-term management to reduce thrombotic risk or pregnancy morbidity. Choosing the type of pharmacological treatment, i.e. the intensity and duration of anticoagulation, depends on the severity of an individual’s APS and the risk of bleeding. This article reviews the current literature on anticoagulation therapy, provides recommendations on when to initiate therapy, and suggests possible alternatives for optimisation of management.
KeywordsAntiphospholipid syndrome (APS) Antiphospholipid (aPL) Systemic lupus erythematosus (SLE) Anticoagulation therapy Intensity Duration Thromboprophylaxis Refractory APS Thrombosis
Conflict of Interest
Sinthiya Punnialingam declares that she has no conflict of interest.
Munther A. Khamashta declares that he has no conflict of interest.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.• Aguilar-Valenzuela R, Martínez-Martínez LA, Pierangeli SS. A Comprehensive Review of Thrombogenic Mechanisms in APS. Open Autoimmun J. 2012;2:58–66. This review evaluates the current literature on in-vivo and in-vitro studies of the different intracellular events induced by aPL Abs and its thrombogenic effects.CrossRefGoogle Scholar
- 8.Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis. 2002;61:46–50.Google Scholar
- 14.•• Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20:206–18. This important report provides a set of recommendations based on systematic reviews and meta-analysis of all studies concerning management of thrombosis in APS with expert opinions from physicians from different specialities involved in APS.PubMedCrossRefGoogle Scholar
- 20.McCarty GA. Hydroxychloroquine (HCQ) treatment in antiphospholipid antibody syndrome (APS): time course of clinical improvement and antiphospholipid antibody (aPL) titer changes over 4 years [abstract]. Arthritis Rheum. 2000;43 Suppl 9:S1061.Google Scholar
- 25.• Cervera R, Khamashta MA, Shoenfeld Y, et al. Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2009;68:1428–32.PubMedCrossRefGoogle Scholar
- 29.Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967–74.PubMedCrossRefGoogle Scholar
- 31.• Pengo V, Ruiz-Irastorza G, Denas G, et al. High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. Autoimmun Rev. 2012;11:577–80. This review evaluates the importance of designing better prospective studies with regard to APS patients and to standardise criteria for APS patients in studies to avoid future conflicting results.PubMedCrossRefGoogle Scholar
- 47.Kumar D, Roubey RA. Use of rituximab in the antiphospholipidsyndrome. Curr Rheumatol Rep. 2010, 12:40–44Google Scholar
- 53.•• Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis rheum. 2012;64:504–12. This article investigates the use of a score which all physicians can easily use in common clinical practice to improve the efficiency of identifying severe APS patients to provide the best possible management.PubMedCrossRefGoogle Scholar
- 54.Sciascia S, Sanna G, Murru V, et al. GAPSS: the Global Antiphospholipid Syndrome Score. Rheumatology. Rheumatology (Oxford). 2013. doi: 10.1093/rheumatology/kes388.